Eukles Asset Management’s Labcorp LH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.99M | Sell |
14,237
-444
| -3% | -$117K | 1.64% | 17 |
|
|
2026
Q1 | $3.92M | Sell |
14,681
-2,180
| -13% | -$590K | 1.75% | 18 |
|
|
2025
Q4 | $4.23M | Sell |
16,861
-110
| -0.6% | -$29.2K | 1.64% | 17 |
|
|
2025
Q3 | $4.87M | Sell |
16,971
-54
| -0.3% | -$14.5K | 1.9% | 13 |
|
|
2025
Q2 | $4.47M | Sell |
17,025
-80
| -0.5% | -$19.5K | 1.83% | 14 |
|
|
2025
Q1 | $3.98M | Buy |
17,105
+228
| +1% | +$55.3K | 1.75% | 16 |
|
|
2024
Q4 | $3.87M | Sell |
16,877
-947
| -5% | -$217K | 1.65% | 18 |
|
|
2024
Q3 | $3.98M | Sell |
17,824
-239
| -1% | -$52.5K | 1.6% | 18 |
|
|
2024
Q2 | $3.68M | Buy |
18,063
+66
| +0.4% | +$13.4K | 1.59% | 18 |
|
|
2024
Q1 | $3.93M | Buy |
17,997
+594
| +3% | +$131K | 1.71% | 17 |
|
|
2023
Q4 | $3.96M | Buy |
17,403
+24
| +0.1% | +$5.04K | 1.87% | 13 |
|
|
2023
Q3 | $3.49M | Sell |
17,379
-2,653
| -13% | -$560K | 1.85% | 15 |
|
|
2023
Q2 | $4.15M | Buy |
20,032
+107
| +0.5% | +$20.8K | 2.12% | 12 |
|
|
2023
Q1 | $3.93M | Sell |
19,925
-113
| -0.6% | -$23.3K | 2.14% | 12 |
|
|
2022
Q4 | $4.05M | Buy |
20,038
+198
| +1% | +$38.7K | 2.37% | 10 |
|
|
2022
Q3 | $3.49M | Sell |
19,840
-71
| -0.4% | -$14.5K | 2.29% | 11 |
|
|
2022
Q2 | $4.01M | Buy |
19,911
+58
| +0.3% | +$12.4K | 2.54% | 9 |
|
|
2022
Q1 | $4.5M | Sell |
19,853
-314
| -2% | -$73.8K | 2.45% | 8 |
|
|
2021
Q4 | $5.44M | Buy |
20,167
+327
| +2% | +$81K | 2.63% | 7 |
|
|
2021
Q3 | $4.8M | Buy |
19,840
+1,010
| +5% | +$255K | 2.62% | 7 |
|
|
2021
Q2 | $4.46M | Buy |
18,830
+949
| +5% | +$216K | 2.47% | 6 |
|
|
2021
Q1 | $3.92M | Buy |
17,881
+561
| +3% | +$113K | 2.53% | 6 |
|
|
2020
Q4 | $3.03M | Buy |
17,320
+379
| +2% | +$65.5K | 2.09% | 13 |
|
|
2020
Q3 | $2.74M | Buy |
16,941
+82
| +0.5% | +$13K | 2.13% | 13 |
|
|
2020
Q2 | $2.4M | Buy |
16,859
+1,703
| +11% | +$236K | 2.05% | 16 |
|
|
2020
Q1 | $1.65M | Sell |
15,156
-1,764
| -10% | -$254K | 1.72% | 18 |
|
|
2019
Q4 | $2.46M | Sell |
16,920
-181
| -1% | -$26.1K | 2% | 15 |
|
|
2019
Q3 | $2.47M | Sell |
17,101
-40
| -0.2% | -$5.84K | 2.14% | 11 |
|
|
2019
Q2 | $2.55M | Sell |
17,141
-90
| -0.5% | -$12.6K | 2.21% | 11 |
|
|
2019
Q1 | $2.27M | Buy |
17,231
+92
| +0.5% | +$11.3K | 2.07% | 13 |
|
|
2018
Q4 | $1.86M | Buy |
+17,139
| New | +$2.3M | 1.94% | 14 |
|
Other funds holding LH
Eukles Asset Management's LH Position: Q2 2026 in Review
Eukles Asset Management reduced its Labcorp (LH) stake by 3% in Q2 2026, selling an estimated $117K and leaving 14,237 shares worth $3.99M. The position accounts for 1.64% of the portfolio, ranked #17.
Eukles Asset Management first reported a position in LH in Q4 2018 and has held it in 31 quarters since. The position peaked at $5.44M in Q4 2021. 1,051 funds tracked by Wall St. Rank hold LH as of Q2 2026.
- Eukles Asset Management held 14,237 shares of Labcorp worth $3.99M as of Q2 2026.
- Eukles Asset Management sold 444 Labcorp shares in Q2 2026, an estimated $117K.
- Labcorp made up 1.64% of Eukles Asset Management's portfolio in Q2 2026, its #17 holding.
- Eukles Asset Management first reported a position in Labcorp in Q4 2018 and has held it in 31 quarters since.
- Eukles Asset Management's Labcorp position peaked at $5.44M in Q4 2021.
- 1,051 funds tracked by Wall St. Rank held Labcorp as of Q2 2026.
Based on Eukles Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.